ADP Ribose Transferases
-
Subject Areas on Research
- A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury.
- Cellular cytoskeleton dynamics modulates non-viral gene delivery through RhoGTPases.
- Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.
- Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck.
- Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma.
- Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome.
- Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.
- Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
- Inhibition of Rho-kinase induces alphaB-crystallin expression in lens epithelial cells.
- Ligation of low-density lipoprotein receptor-related protein with antibodies elevates intracellular calcium and inositol 1,4, 5-trisphosphate in macrophages.
- Modulation of Rho GTPase activity alleviates chondroitin sulfate proteoglycan-dependent inhibition of neurite extension.
- Nicotinamide adenine dinucleotide (NAD) and its metabolites inhibit T lymphocyte proliferation: role of cell surface NAD glycohydrolase and pyrophosphatase activities.
- Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy.
- Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.
- Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner.
- Receptor-associated protein binding blocks ubiquitinylation of the low density lipoprotein receptor-related protein.
- Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.
- Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.
- Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.